131-I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma
131-I-间碘苄基胍治疗恶性嗜铬细胞瘤
基本信息
- 批准号:7594211
- 负责人:
- 金额:$ 7.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Adrenal MedullaBenignBiodistributionCellsChemoembolizationDiseaseDrug KineticsEffectivenessEnhancersIn complete remissionIodine I 131 MetaiodobenzylguanidineLaboratoriesLife ExpectancyMalignant - descriptorMalignant PheochromocytomaNeuroendocrine TumorsNumbersOctreotideOperative Surgical ProceduresPalliative CarePatientsPharmaceutical PreparationsPharmacologic SubstancePheochromocytomaProtocols documentationRangeSafetySympathetic GangliaTestingTumor Burdenchemotherapyneoplastic cellsizetumoruptake
项目摘要
Pheochromocytomas are neuroendocrine tumors that develop from cells in the adrenal medulla or sympathetic ganglion. Most of these tumors are benign but 10 to 30% are malignant with life expectancy ranging 3 to 5 years. Other than surgery for local disease, there is no known curative treatment for malignant pheochromocytoma. Current therapies for widespread metastatic disease include chemotherapy, chemoembolization, octreotide, and 131I-MIBG. In general these treatments are palliative but very few patients have had complete responses
This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-MIBG, and in particular tests whether pre-treatment using specific drugs (so called sentitizers) increases the efficacy of 131I-MIBG treatment. Recently, the protocol has been on hold to find a laboratory that will supply us with 131I-MIBG.
嗜铬细胞瘤是一种神经内分泌肿瘤,起源于肾上腺髓质或交感神经节的细胞。这些肿瘤大多数是良性的,但10%至30%是恶性的,预期寿命为3至5年。恶性嗜铬细胞瘤除了手术治疗局部疾病外,目前还没有已知的根治性治疗方法。目前广泛转移性疾病的治疗包括化疗、化疗栓塞、奥曲肽和131 I-MIBG。一般来说,这些治疗是姑息性的,但很少有患者有完全的反应
该项目测试使用131 I-MIBG放射毒性治疗恶性嗜铬细胞瘤的疗效,特别是测试使用特定药物(所谓的增敏剂)进行预治疗是否会增加131 I-MIBG治疗的疗效。最近,该协议已被搁置,以寻找一个实验室,将提供给我们131 I-MIBG。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karel Pacak其他文献
Karel Pacak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karel Pacak', 18)}}的其他基金
131I-Metaiodobenzylguanidine Therapy of Pheochromocytoma
131I-间碘苄胍治疗嗜铬细胞瘤
- 批准号:
6813962 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
131-I-Metaiodobenzylguanidine Treatment of Malignant Phe
131-I-间碘苄基胍治疗恶性 Phe
- 批准号:
7334117 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
Diagnosis, Pathophysiology And Molecular Biology Of Pheochromocytoma
嗜铬细胞瘤的诊断、病理生理学和分子生物学
- 批准号:
7734764 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
Diagnosis, Pathophysiology And Molecular Biology Of Pheo
Pheo 的诊断、病理生理学和分子生物学
- 批准号:
7209915 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
131-I-Metaiodobenzylguanidine Treatment of Malignant Phe
131-I-间碘苄基胍治疗恶性 Phe
- 批准号:
7006751 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
New Imaging Modalities In The Evaluation Of Patients Wit
评估患者机智的新成像方式
- 批准号:
6659606 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
Diagnosis, Pathophysiology And Molecular Biology Of Pheochromocytoma
嗜铬细胞瘤的诊断、病理生理学和分子生物学
- 批准号:
8553901 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
Diagnosis, Pathophysiology And Molecular Biology of Pheochromocytoma and Paraganglioma
嗜铬细胞瘤和副神经节瘤的诊断、病理生理学和分子生物学
- 批准号:
9339254 - 财政年份:
- 资助金额:
$ 7.41万 - 项目类别:
相似海外基金
Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
- 批准号:
23K08495 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
- 批准号:
22KJ2498 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
- 批准号:
10726042 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
- 批准号:
23H03765 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
- 批准号:
23K08075 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
- 批准号:
10720034 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
- 批准号:
2306943 - 财政年份:2023
- 资助金额:
$ 7.41万 - 项目类别:
Standard Grant
Towards Achieving Zero Emissions through the use of an Environmentally Benign Non-Regenerable Solvent to Capture CO2 from Large Point Source Emitters for Direct Permanent Storage in Geological Formation or Usage in Accelerated Curing of Ready-mix Con
通过使用环境友好的不可再生溶剂从大型点源排放器捕获二氧化碳,直接永久储存在地质构造中或用于预拌混凝土的加速固化,从而实现零排放
- 批准号:
RGPIN-2022-03431 - 财政年份:2022
- 资助金额:
$ 7.41万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




